ASIT biotech reaches another key milestone by finalizing the industrialization process for the manufacture of clinical batches of its hdm-ASIT+™ product candidate for house dust mite allergy

- This crucial step has allowed the Company to launch the final preclinical developments required by the authorities ahead of a clinical trial
- A first batch of hdm-ASIT+™ was manufactured on ASIT biotech’s new unit for producing GMP-compliant clinical batches for Phase I and II studies
- The Company plans to submit an application for a first-in-man clinical trial authorization by the end of the first half of 2019

Brussels, Belgium, December 17, 2018 – 7.00 am CET – ASIT biotech (ASIT - BE0974289218), a Belgian biopharmaceutical company specialized in the research and development of innovative allergy immunotherapy products, today announced that it has finalized the industrialization process for the manufacture of clinical batches of its hdm-ASIT+™ product candidate. They will be used in its initial Phase I/II clinical trials as a treatment for patients with house dust mite allergy.

After gp-ASIT+™, its flagship product for treating grass pollen-induced rhinitis currently in Phase III, hdm-ASIT+™ is ASIT biotech’s second product candidate for respiratory allergies, and more specifically for house dust mite allergy. It was selected in June 2018 on the basis of in vitro tests undertaken by the team led by Professor Mohamed Shamji (Imperial College London) on the blood cells of allergic patients. The initial in vitro tests revealed that these peptides trigger less of an allergic reaction than full allergens while rapidly stimulating the appropriate immune system regulating mechanisms.

The industrialization of the hdm-ASIT+™ manufacturing process is a crucial stage in the development process, as it guarantees the homogeneity of all batches manufactured for clinical trials on the product through to its market approval.

Thierry Legon, CEO of ASIT biotech, commented: “Our development strategy in respiratory allergies is progressing well. The finalization of the industrialization process for manufacturing our new hdm-ASIT+™ product candidate for treating house dust mite allergy represents a major milestone prior to launching clinical trials. A first batch of hdm-ASIT+™ has been successfully obtained in our new pilot unit. We are confident that in coming months we will be able to use these new premises to produce the first clinical batches of house dust mite and peanut peptides. The final preclinical stages are underway prior to the launch of a first clinical trial for which we hope to submit an application for authorization by the end of the first half of 2019”.

***

About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of allergy immunotherapy (AIT) product candidates consisting of a unique 1

1 GMP - Good Manufacturing Practices
mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline contains three novel ASIT+™ product candidates targeting respiratory allergies with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), and food allergies (peanut allergy: pnt-ASIT+™) that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 26 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at www.asitbiotech.com

Contacts

Company
Thierry Legon, CEO
ASIT biotech
Tel.: +32 2 264 03 90
investors@asitbiotech.com

Media and Investor Relations - France
NewCap
Dusan Oresansky / Pierre Laurent
Tel.: +33 1 44 71 94 92
asitbiotech@newcap.eu

Media Relations - Belgium
Laure-Eve Monfort
Tel.: +32 2 290 90 93
monfort@comfi.be

Forward-looking statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Legal notice - The Company is responsible for the information contained in this press release. This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.